Sharon Frey

Summary

Affiliation: Saint Louis University
Country: USA

Publications

  1. pmc Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults
    Sharon E Frey
    Saint Louis University School of Medicine, Division of Infectious Diseases and Immunology, St Louis, MO 63104, USA
    Vaccine 28:6367-73. 2010
  2. doi request reprint A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA
    Sharon E Frey
    Saint Louis University, School of Medicine, Center for Vaccine Development, St Louis, MO, USA Electronic address
    Vaccine 31:4874-80. 2013
  3. pmc Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario
    Sharon E Frey
    Division of Infectious Diseases, Allergy and Immunology, Saint Louis University School of Medicine, St Louis, MO 63104, USA
    Vaccine 31:3025-33. 2013
  4. pmc Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations
    Sharon E Frey
    Division of Infectious Diseases, Allergy and Immunology, Saint Louis University School of Medicine, St Louis, MO 63104, USA
    J Infect Dis 206:828-37. 2012
  5. pmc Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge
    Sharon E Frey
    Department of Medicine, Saint Louis University School of Medicine and National Institute of Allergy and Infectious Diseases Vaccine Treatment and Evaluation Unit, 1100 S Grand Blvd DRC 8, St Louis, MO 63104, USA
    Vaccine 25:8562-73. 2007
  6. doi request reprint Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults
    Sharon E Frey
    Division of Infectious Diseases and Immunology, Department of Internal Medicine, Saint Louis University School of Medicine, 1100 S Grand Blvd DRC 8th Floor, St Louis, MO 63104, United States
    Vaccine 27:1637-44. 2009
  7. ncbi request reprint Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults
    Sharon Frey
    Saint Louis University School of Medicine, Saint Louis, MO, USA
    Vaccine 21:4234-7. 2003
  8. ncbi request reprint High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects
    Paul A Goepfert
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
    J Infect Dis 192:1249-59. 2005
  9. pmc Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine
    Frances K Newman
    Saint Louis University Vaccine Treatment and Evaluation Unit, St Louis, Missouri 63110, USA
    J Clin Microbiol 41:3154-7. 2003
  10. ncbi request reprint Dose-related effects of smallpox vaccine
    Sharon E Frey
    Department of Medicine, National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit, Saint Louis University School of Medicine, St Louis, USA
    N Engl J Med 346:1275-80. 2002

Collaborators

Detail Information

Publications26

  1. pmc Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults
    Sharon E Frey
    Saint Louis University School of Medicine, Division of Infectious Diseases and Immunology, St Louis, MO 63104, USA
    Vaccine 28:6367-73. 2010
    ..We describe the first in humans clinical trial of this prophylactic HCV vaccine...
  2. doi request reprint A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA
    Sharon E Frey
    Saint Louis University, School of Medicine, Center for Vaccine Development, St Louis, MO, USA Electronic address
    Vaccine 31:4874-80. 2013
    ....
  3. pmc Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario
    Sharon E Frey
    Division of Infectious Diseases, Allergy and Immunology, Saint Louis University School of Medicine, St Louis, MO 63104, USA
    Vaccine 31:3025-33. 2013
    ....
  4. pmc Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations
    Sharon E Frey
    Division of Infectious Diseases, Allergy and Immunology, Saint Louis University School of Medicine, St Louis, MO 63104, USA
    J Infect Dis 206:828-37. 2012
    ....
  5. pmc Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge
    Sharon E Frey
    Department of Medicine, Saint Louis University School of Medicine and National Institute of Allergy and Infectious Diseases Vaccine Treatment and Evaluation Unit, 1100 S Grand Blvd DRC 8, St Louis, MO 63104, USA
    Vaccine 25:8562-73. 2007
    ..IMVAMUNE vaccination prior to Dryvax reduced virus replication at the Dryvax site, decreased the size of the primary cutaneous lesion, and decreased the time to healing but did not completely ameliorate the immune response...
  6. doi request reprint Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults
    Sharon E Frey
    Division of Infectious Diseases and Immunology, Department of Internal Medicine, Saint Louis University School of Medicine, 1100 S Grand Blvd DRC 8th Floor, St Louis, MO 63104, United States
    Vaccine 27:1637-44. 2009
    ..0x10(8)PFU/mL. All subjects had a primary skin reaction indicating a successful vaccination. The adverse events, 4-fold neutralizing antibody rise and T cell immune responses were similar between the groups...
  7. ncbi request reprint Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults
    Sharon Frey
    Saint Louis University School of Medicine, Saint Louis, MO, USA
    Vaccine 21:4234-7. 2003
    ..Compared with Fluzone, FLUAD was associated with increased immunogenicity and mild post-immunization reactions in healthy adults. The magnitude of increased immunogenicity in healthy adults was less than that seen in elderly populations...
  8. ncbi request reprint High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects
    Paul A Goepfert
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
    J Infect Dis 192:1249-59. 2005
    ..0) TCID50 (60 participants) than when given at the regular dose, 10(7.26) TCID50 (40 participants); as a control, a placebo vaccine preparation also was administered (10 participants)...
  9. pmc Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine
    Frances K Newman
    Saint Louis University Vaccine Treatment and Evaluation Unit, St Louis, Missouri 63110, USA
    J Clin Microbiol 41:3154-7. 2003
    ..Therefore, the more sensitive, specific, and reproducible plaque neutralization assay for the detection of antibody to vaccinia virus is the method using a 15-h-incubation time and freshly sonicated vaccinia virus...
  10. ncbi request reprint Dose-related effects of smallpox vaccine
    Sharon E Frey
    Department of Medicine, National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit, Saint Louis University School of Medicine, St Louis, USA
    N Engl J Med 346:1275-80. 2002
    ....
  11. pmc Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax
    D Huw Davies
    University of California Irvine, Department of Medicine Division of Infectious Diseases, 3501 Hewitt Hall, Irvine, CA 92697, USA
    J Virol 82:652-63. 2008
    ..The work supports other information suggesting that MVA may be a useful alternative to Dryvax...
  12. pmc Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults
    Robert B Belshe
    Saint Louis University Medical Center, St Louis, MO 63110, United States
    Vaccine 25:6755-63. 2007
    ..ID route was not superior to IM vaccine at inducing antibodies. ID vaccine induced significantly more local inflammatory response than IM vaccine...
  13. pmc Antibody responses to vaccinia membrane proteins after smallpox vaccination
    Steven J Lawrence
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO 63110, USA
    J Infect Dis 196:220-9. 2007
    ..Vaccinia virus (VV) membrane proteins are candidates for orthopoxvirus subunit vaccines and potential targets for therapeutic antibodies. Human antibody responses to these proteins after VV vaccination have not been well characterized...
  14. ncbi request reprint The immunogenetics of smallpox vaccination
    Samuel L Stanley
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Infect Dis 196:212-9. 2007
    ....
  15. pmc Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial
    Nina D Russell
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 44:203-12. 2007
    ..We conducted a phase 2 trial to determine if a canarypox vaccine candidate (vCP1452) administered with rgp120 subunit protein would "qualify" for a trial to define a correlate of efficacy...
  16. pmc Lack of transmission of vaccinia virus
    James H Stark
    Emerg Infect Dis 12:698-700. 2006
  17. ncbi request reprint Clinical responses to undiluted and diluted smallpox vaccine
    Sharon E Frey
    Department of Medicine, National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit, Saint Louis University School of Medicine, St Louis, USA
    N Engl J Med 346:1265-74. 2002
    ..To evaluate the potential to increase the supply of smallpox vaccine (vaccinia virus), we compared the response to vaccination with 10(8.1), 10(7.2), and 10(7.0) plaque-forming units (pfu) of vaccinia virus per milliliter...
  18. ncbi request reprint Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax
    Frances K Newman
    Saint Louis University, St Louis, Missouri, USA
    J Infect Dis 187:1319-22. 2003
    ....
  19. ncbi request reprint Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination
    Jeffrey S Kennedy
    Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    J Infect Dis 190:1286-94. 2004
    ..Postvaccination cell-mediated immune (CMI) responses have not been compared by use of controlled trials in previously vaccinated (vaccinia-nonnaive) and nonvaccinated (vaccinia-naive) individuals...
  20. ncbi request reprint Dose-dependent neutralizing-antibody responses to vaccinia
    Robert B Belshe
    Center for Vaccine Development, Saint Louis University School of Medicine, St Louis, Missouri 63110, USA
    J Infect Dis 189:493-7. 2004
    ..Larger lesion size and fever after vaccination were associated with significantly higher neutralizing-antibody titers after vaccination...
  21. ncbi request reprint Response to smallpox vaccine in persons immunized in the distant past
    Sharon E Frey
    Department of Medicine, Saint Louis University School of Medicine and National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit, MO, USA
    JAMA 289:3295-9. 2003
    ..There is renewed interest in use of smallpox vaccine due to the potential for a bioterrorist attack. This would involve vaccinating health care workers who were previously vaccinated...
  22. ncbi request reprint Immune status in a primary smallpox vaccinee who failed to develop an immunization site reaction
    John M Kelso
    JAMA 293:677-8. 2005
  23. ncbi request reprint Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions
    Getahun Abate
    Department of Internal Medicine, Saint Louis University, St Louis, Missouri 63110, USA
    J Infect Dis 192:1362-71. 2005
    ..CFSE-based flow-cytometric assays will be useful in evaluating cell-mediated immune responses induced by new smallpox vaccines...
  24. ncbi request reprint Safety profile of recombinant canarypox HIV vaccines
    Guy de Bruyn
    HIV Vaccines Trials Network Core Operations, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Vaccine 22:704-13. 2004
    ..Reactogenicity does not appear to be related to the number or type of inserted genes, and did not vary between different ALVAC constructs...
  25. ncbi request reprint Unique risks to volunteers in HIV vaccine trials
    Sharon E Frey
    Division of Infectious Diseases and Immunology, Saint Louis University School of Medicine, 3635 Vista Ave FDT 8N, St Louis, MO 63110, USA
    J Investig Med 51:S18-20. 2003
    ..The conduct of HIV vaccine trials has forced a constant re-evaluation of the risk-to-benefit ratio related to trial participation and a challenge to the ethics surrounding vaccine research...
  26. ncbi request reprint Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A
    Kalpana Gupta
    Department of Medicine, University of Washington, Seattle, Washington, USA
    J Acquir Immune Defic Syndr 29:254-61. 2002
    ..This high-titered preparation of ALVAC-HIV vCP205 in combination with gp120 was safe and immunogenic in a diverse group of HIV-1-seronegative volunteers...